MedTrace Logo

Phase 1 Study With Sorafenib and Sirolimus

NCT00509613 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2009-09-18

No results posted yet for this study

Summary

The purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for combination therapy in subsequent phase 2 trials.

Conditions

  • Advanced Solid Tumor
  • Refractory to Standard Therapies

Interventions

DRUG

Sorafenib

DRUG

Sirolimus

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • C.M.L. van Herpen, MD, PhD · UMC St Radboud

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00509613 on ClinicalTrials.gov